Limits...
Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus

Mouse body weight changes in each treatment group during the first 32 days of the trial.  Mice were treated with 9 mg/kg doxorubicin (calculated doxorubicin equivalents) or saline dilution buffer at day 0, 3 and 6.  All values are expressed as mean of 9 mice.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3066593&req=5

fig9: Mouse body weight changes in each treatment group during the first 32 days of the trial. Mice were treated with 9 mg/kg doxorubicin (calculated doxorubicin equivalents) or saline dilution buffer at day 0, 3 and 6. All values are expressed as mean of 9 mice.

Mentions: Mouse body weights were monitored throughout the study period (Figure 9). Each doxorubicin regimen (CTT2-SL liposome, Caelyx, and Doxorubicin) induced a slight weight decrease with a maximum loss of about 10% at day 9. However, one week later, body weights returned to initial levels.


Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Mouse body weight changes in each treatment group during the first 32 days of the trial.  Mice were treated with 9 mg/kg doxorubicin (calculated doxorubicin equivalents) or saline dilution buffer at day 0, 3 and 6.  All values are expressed as mean of 9 mice.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3066593&req=5

fig9: Mouse body weight changes in each treatment group during the first 32 days of the trial. Mice were treated with 9 mg/kg doxorubicin (calculated doxorubicin equivalents) or saline dilution buffer at day 0, 3 and 6. All values are expressed as mean of 9 mice.
Mentions: Mouse body weights were monitored throughout the study period (Figure 9). Each doxorubicin regimen (CTT2-SL liposome, Caelyx, and Doxorubicin) induced a slight weight decrease with a maximum loss of about 10% at day 9. However, one week later, body weights returned to initial levels.

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus